Ligand Pharmaceuticals (LGND) Interest & Investment Income (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Interest & Investment Income of $6.7 million for Q1 2026, up 4.1% sequentially from $6.4 million in Q4 2025, and up 275.78% YoY from $1.8 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Interest & Investment Income (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Interest & Investment Income for 13 years, with the latest figure at $6.7 million in Q1 2026.
- Quarterly Interest & Investment Income rose 275.78% year-over-year to $6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.5 million (up 137.55% YoY) and the FY2025 annual result came in at $13.7 million, up 69.57% from the prior year.
- Interest & Investment Income climbed to $6.7 million in Q1 2026 per LGND's latest filing, from $6.4 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $6.7 million in Q1 2026 and troughed at $134000.0 in Q1 2022.
- A 5-year average of $2.2 million and a median of $1.8 million in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2023: Interest & Investment Income plunged 54.73% in 2022, then surged 970.9% in 2023.
- Over 5 years, Interest & Investment Income stood at $1.0 million in 2022, then jumped by 65.49% to $1.7 million in 2023, then climbed by 14.06% to $1.9 million in 2024, then surged by 231.07% to $6.4 million in 2025, then grew by 4.1% to $6.7 million in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $6.7 million, $6.4 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 7.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.30 Mn |
| Mar 31, 2026 | 6.66 Mn |
| Dec 31, 2025 | 6.39 Mn |
| Sep 30, 2025 | 3.87 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Mar 31, 2025 | 1.77 Mn |
| Dec 31, 2024 | 1.93 Mn |
| Sep 30, 2024 | 1.35 Mn |
| Jun 30, 2024 | 2.76 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Dec 31, 2023 | 1.69 Mn |
| Sep 30, 2023 | 2.26 Mn |
| Jun 30, 2023 | 2.32 Mn |
| Mar 31, 2023 | 1.44 Mn |
| Dec 31, 2022 | 1.02 Mn |
| Sep 30, 2022 | 591,000.00 |
| Jun 30, 2022 | 298,000.00 |
| Mar 31, 2022 | 134,000.00 |
| Dec 31, 2021 | 188,000.00 |
| Sep 30, 2021 | 169,000.00 |